CommercialPrior AuthMedium impact
08.01.79g, Dostarlimab-gxly (Jemperli)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
The medical necessity criteria for Dostarlimab-gxly (Jemperli), a cancer immunotherapy drug, have been updated for commercial insurance plans. This affects billing and prior authorization requirements for this specialty oncology medication.
Action Required
Before June 1, 2026: Billing and clinical teams must review updated medical necessity criteria for Dostarlimab-gxly (Jemperli) prescriptions. Update prior authorization workflows and ensure documentation meets new criteria requirements. Verify with IBX commercial plans before billing to prevent claim denials.